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Vaccination through the natural route of infection represents an attractive immunization
strategy in vaccinology. In the case of tuberculosis, vaccine delivery by the respiratory
route has regained interest in recent years, showing efficacy in different animal models.
In this context, respiratory vaccination triggers lung immunological mechanisms which
are omitted when vaccines are administered by parenteral route. However, contribution
of mucosal antibodies to vaccine- induced protection has been poorly studied. In the
present study, we evaluated in mice and non-human primates (NHP) a novel whole
cell inactivated vaccine (MTBVAC HK), by mucosal administration. MTBVAC HK given
by intranasal route to BCG-primed mice substantially improved the protective efficacy
conferred by subcutaneous BCG only. Interestingly, this improved protection was absent
in mice lacking polymeric Ig receptor (pIgR), suggesting a crucial role of mucosal
secretory immunoglobulins in protective immunity. Our study in NHP confirmed the
ability of MTBVAC HK to trigger mucosal immunoglobulins. Importantly, in vitro assays
demonstrated the functionality of these immunoglobulins to induce M. tuberculosis
opsonization in the presence of human macrophages. Altogether, our results suggest
that mucosal immunoglobulins can be induced by vaccination to improve protection
against tuberculosis and therefore, they represent a promising target for next generation
tuberculosis vaccines.
Keywords: whole-cell vaccine, pulmonary vaccination, animal models, mucosal immunoglobulins, opsonization,
tuberculosis
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INTRODUCTION
Tuberculosis (TB) disease causes one and a half million deaths per
year, and is one of the leading infectious diseases affecting mainly
developing and underdeveloped countries. The rising spread of
multidrug resistant strains with increasing human migration
makes TB an alarming global health problem, according to World
Health Organization (WHO). Therefore, there is an urgent need
for new effective TB vaccines.
Vaccination through the natural route of infection represents
an attractive strategy for priming the natural host immunity.
In the case of TB, respiratory mucosal tissue is the primary
site for establishment of infection. It has been well described
in different preclinical models that vaccination with BCG by
the respiratory route confers a substantially improved protection
in comparison to subcutaneous or intradermal immunization
(Lagranderie et al., 1993; Aguilo et al., 2016; Dijkman et al.,
2019). Indeed, in the last few years, it has raised an interest
in exploring new vaccination approaches delivered through
respiratory routes of administration. These strategies include
attenuated M. tuberculosis (Kaushal et al., 2015) in addition to
BCG, as well as subunit vaccines formulated with adjuvants or
non-replicative virus (Stylianou et al., 2015; Woodworth et al.,
2019). In 2014, the first clinical trial of an aerosol tuberculosis
vaccine was reported (Satti et al., 2014).
It is assumed that inactivation of whole-cell tuberculosis
vaccines reduces their immunogenic and protective potential.
Nevertheless, and likely based on safety concerns described for
live BCG under specific conditions (e.g., immunodeficiencies),
researchers have explored the use of inactivated vaccine
approaches for tuberculosis. To overcome the loss of
immunogenicity, different strategies have been conducted,
such as the use of inactivated whole-cell vaccines as booster for
BCG (Von Reyn et al., 2017).
The present work describes vaccination with a heat-killed
(HK) version of the live attenuated M. tuberculosis vaccine
MTBVAC (Arbues et al., 2013) both in mice and non-human
primates (NHP). MTBVAC is the first and only live attenuated
tuberculosis vaccine based on M. tuberculosis that has reached
clinical stages of development, and it has shown an excellent
safety profile both in adults and newborns, as well as stronger
immunogenicity compared to BCG (Spertini et al., 2015; Tameris
et al., 2019). Results in the present study demonstrate improved
efficacy of MTBVAC HK when given by intranasal route to
mice previously vaccinated with subcutaneous BCG. In addition,
we interrogated lung humoral immune responses elicited by
MTBVAC HK in mice and NHP, finding an induction of
tuberculosis-specific mucosal immunoglobulins with functional
activity against M. tuberculosis.
RESULTS
Intranasal MTBVAC HK Enhances
Protection Conferred by Subcutaneous
BCG
We and others have previously demonstrated an advantageous
vaccine-induced protection of whole-cell live vaccines when
given by respiratory route, compared to subcutaneous or
intradermal administration in immunologically naïve subjects
(Aguilo et al., 2016). Since respiratory airways could be a
sensitive organ for exacerbated inflammatory response caused
by live bacteria in the pre-exposed, we chose to evaluate
the efficacy of an inactivated whole cell vaccine as a booster
strategy after primary BCG. To this end, we inactivated
MTBVAC building upon the promising immunogenic profile
shown by the live version of this vaccine both in animal
models and in humans (Marinova et al., 2017). MTBVAC
was inactivated by heating the vaccine at 100◦C for 30 min.
Bacterial inactivation was confirmed by plating on 7H10
solid agar medium (data not shown). Bacteria visualization
using electron microscopy confirmed that MTBVAC maintained
their bacillary shape upon heat treatment (Supplementary
Figure S1). Then, we characterized MTBVAC HK-conferred
protection in mice under different experimental conditions.
First, 107 MTBVAC HK bacteria were inoculated intranasally
in naïve or in BCG-primed mice. One month later, mice were
challenged intranasally with a low dose (150 CFU) of the H37Rv
Mtb strain. After one month, mice were sacrificed and lung
bacterial load evaluated by plating in solid medium. Our data
showed that MTBVAC HK alone did not confer protection
compared to unvaccinated control. However, when combined
with subcutaneous BCG priming, protection was about one-log
higher than that provided by BCG only (Figure 1A), indicating
the need of a BCG prime to trigger a MTBVAC HK-induced
protective response.
We also evaluated protection induced by MTBVAC killed
with formalin, since this method of inactivation had been
shown in a previous study with other inactivated vaccines to
better preserve immunogenicity compared to heating (Cryz
et al., 1982). However, in this case, we did not find any
difference in efficacy between both MTBVAC inactivation
methods (Supplementary Figure S2). Since heat-inactivation
is easier to implement, we continued vaccine characterization
using this method of inactivation. MTBVAC HK induced
better protection only when given by intranasal route, but
did not improve BCG when administered subcutaneously
(Figure 1B). Ultimately, our data show that the MTBVAC
HK booster effect was dose-dependent, as we only observed
improved protection with a high dose of MTBVAC HK
(107), whereas no effect was obtained using 104 bacteria
(Figure 1C). We and others have previously reported the lack
of protection induced by BCG subcutaneous in the mouse
strain DBA/2 (Aguilo et al., 2016). Interestingly, MTBVAC
HK also induced protection in BCG-vaccinated DBA/2 mice,
suggesting that this vaccination approach could confer protective
efficacy in cases in which BCG is ineffective (Supplementary
Figure S3). Comparison of different independent lots of
MTBVAC HK provided a similar protective profile, superior
to BCG only, evidencing the reproducibility of our results
(Supplementary Figure S4).
Considering that BCG is primarily administered in the clinic
in newborn populations, we used a neonatal mouse model
in which BCG was inoculated at birth, and MTBVAC HK
given 8 weeks later, when the immune system has reached
a mature status. Protection by Mtb reduction in lungs was
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FIGURE 1 | Improved protection induced by intranasal MTBVAC HK as boost of subcutaneous BCG. (A–C) Groups of C57BL/6 adult mice where vaccinated with
BCG and MTBVAC HK 4 weeks apart (107 MTBVAC HK dose when not specified). After one month, mice were intranasally challenged with H37Rv and lung
bacterial load analyzed one month later. (D,E) Newborn mice were vaccinated with BCG and 8 weeks later boosted intranasally with 107 MTBVAC HK. Mice were
challenged with a low-dose (D) or a high-dose (E) H37Rv inoculation and lung CFUs or survival analyzed, respectively. (F,G) Antigen-specific IFNg and IL17A
production one month after MTBVAC HK vaccination, following PPD stimulation of cells from lungs (F) and spleen (G). (A–D, F,G) Data are shown as mean ± SEM
and are representative of at least two independent experiments. (n = 6 mice/group). *p < 0.05; **p < 0.001; ***p < 0.001; ****p < 0.0001 by one-way ANOVA and
Bonferroni post-test. (E) Data from one experiment (n = 10 mice/group) are represented in a Kaplan-Meier survival curve and statistical significance calculated by a
LogRank test. **p < 0.01.
significantly improved in the MTBVAC HK booster group
(Figure 1D), and comparable to the protection level observed
in adult mice immunized with BCG. We also evaluated vaccine
efficacy by survival as a readout in a high-dose, mouse challenge
model and found that intranasal MTBVAC HK boosting
substantially extended mouse survival in comparison to BCG sc
immunization (Figure 1E).
Although we did not investigate other administration routes,
our results suggest that the beneficial effect of MTBVAC
HK boosting specifically depends on its interaction with the
respiratory mucosal immune system. Therefore we analyzed
cellular responses in lungs as well as in spleen after ex vivo
stimulation with M. tuberculosis secreted antigens (Purified
protein derivative: PPD). Data revealed that MTBVAC HK
intranasal boosting enhanced antigen-specific IFNγ and IL17
induction in lungs (Figure 1F). In addition, spleen response
profiling also revealed a higher IFNγ and IL17 production at a
systemic level elicited by MTBVAC HK boosting (Figure 1G).
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FIGURE 2 | Intranasal MTBVAC HK induces mucosal immunoglobulins in respiratory airways. (A–C) Groups of C57BL/6 adult mice where vaccinated with BCG and
MTBVAC HK 4 weeks apart. One month later PPD- specific IgA, IgM, IgG in BAL samples. (D–F) One month after MTBVAC HK boosting, wild-type, IgA-/- and
pIgR-/- mice were intranasally challenged with H37Rv and lung bacterial load analyzed one month later. All data are mean ± SEM (A–C) Data are representative of
two independent experiments (n = 6 mice/group). (D–F) Data in the graphs represent a pool of two independent experiments (n = 12 mice/group). *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001 by one-way ANOVA and Bonferroni post-test.
Intranasal MTBVAC HK Induces
Protective Secretory Immunoglobulins
We have previously reported that respiratory, but not
subcutaneous live BCG, triggered IgA production in
respiratory airways (Aguilo et al., 2016). Thus, we next
assessed whether intranasal MTBVAC HK induced PPD-specific
immunoglobulins, including IgA, IgM and IgG subtypes, in
bronchoalveolar lavage (BAL) (Figures 2A–C). MTBVAC
HK booster vaccination triggered an increase of the three
types of antibodies compared to unvaccinated and BCG
only control groups.
To assess contribution of mucosal secretory immunoglobulins
(sIg) to MTBVAC HK-mediated protection, we tested vaccine-
conferred protective efficacy in mice deficient by genetic
knockout for IgA (igha-/-) or for the polymeric immunoglobulin
receptor (pIgR-/-). This latter molecule is a protein transporter
highly expressed in mucosal tissues, which binds to J chain
to actively translocate multimeric IgA or IgM across mucosal
epithelium, and therefore lack of pIgR leads to retention of
multimeric sIg in the mucosal lamina propria, preventing their
active transport over the mucosal barrier (Kaetzel et al., 1991).
Our results revealed a similar protection provided by intranasal
MTBVAC HK in igha-/- mice when compared to wild type
(Figures 2D,E) suggesting no specific protective role of IgA.
Conversely, MTBVAC HK-specific protection was completely
abrogated in the absence of pIgR (Figure 2F). Altogether, this
result would indicate a crucial contribution of sIg to protective
efficacy mediated by MTBVAC HK, suggesting a substantial
contribution of sIgM rather than sIgA. Remarkably, pIgR-/- mice
did not show less protection by BCG s.c, suggesting that sIg has
no role in systemic vaccine-induced protection.
Mucosal MTBVAC-HK Booster
Vaccination in NHP
MTBVAC-HK was further evaluated as a booster vaccine in
a non-human primate (NHP) vaccination and infection study
to address tolerability, immunogenicity and protective efficacy
in the primate host. Adult rhesus macaques (Macaca mulatta)
were vaccinated either with BCG only, or with BCG followed
by a MTBVAC-HK booster by pulmonary mucosal instillation
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FIGURE 3 | Intrabronchial MTBVAC HK boosting induces local and systemic tuberculosis-specific cellular responses in NHP. (A) A study design schematic shows
the time lines on a weekly basis relative to primary BCG vaccination and infectious challenge with M. tuberculosis, including booster immunization and biosampling
events. (B,C) PPD-specific IFNg responses in peripheral blood were measured by ELISPOT immediately prior to and 1 week after MTBVAC HK boosting, at week 16
and 17, respectively. Individual data points are consistently colored according to the Supplementary Table 1; fat horizontal lines indicate group medians. Also, flow
cytometry after intracellular cytokine staining was used to analyze IFNg responses. Dot plots of CD28 versus IFNg specific fluorescence signals of CD4 + T
lymphocytes from a representative BAL sample illustrate local IFNg production (D) in the absence and (E) in the presence of PPD recall stimulation in vitro.
Percentages per individual of PPD-induced IFNg-positive (F) CD4+ and (G) CD8+T lymphocytes from BAL are depicted.
16 weeks later (Figure 3A). One group was left untreated as non-
vaccinated controls. Twenty-five weeks after primary vaccination
all animals were challenged by endobronchial instillation of 50
colony forming units (CFU) of Mtb strain Erdman, with a follow-
up of 12 weeks until study endpoint and post-mortem evaluation
of infection and disease (Figure 3A). (See Supplementary Table 1
for an overview of animals per treatment group).
Within the limits of observation, animals tolerated mucosal
MTBVAC-HK boosting well; we did not observe any adverse
events. Measuring vaccine-induced responses by specific
interferon-gamma (IFNg) ELISPOT, using PBMC and antigenic
recall stimulation with PPD, MTBVAC-HK boosting induced
a transient elevation of the frequency of IFNg producing
cells in the periphery at week 17 (one week post MTBVAC
HK immunization) relative to the response induced by
BCG (p = 0.0997 by non-parametric Mann-Whitney testing;
Figures 3B,C). This increase was found to be transient since
MTBVAC HK-specific T cell response dropped sharply at week
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20 (Supplementary Figure S5A). Locally, and examining three
pre-assigned animals out of six of the MTBVAC-HK boosted
animals only (comparing week 13 versus week 20 post-BCG), we
registered a clear influx of cells into the lung lumen upon mucosal
MTBVAC-HK boosting and the induction of IFNg-positive
CD4+ and CD8+ T lymphocytes (Figures 3D–G).
Upon infectious challenge with Mtb, highest pathology scores
and lung bacterial counts were obtained in 3 non-vaccinated
control (nv.ctrl) animals (Figures 4A–D, and Supplementary
Figures S5B,C). However, there was an unexpected large spread
in pathological involvement, with three out of six unvaccinated
controls showing relatively mild disease levels (for which we
have no explanation at this point), which altered all the
statistical comparisons. Both BCG vaccinees and the MTBVAC-
HK boosted animals revealed lower pathology scores by group
median values (except for extrathoracic dissemination), but
without statistical significance (Figures 4A–C). Likewise, there
was no statistically significant vaccine effect by enumeration
of Mtb at necropsy from lung (Figure 4D) or hilar lymph
node and spleen (Supplementary Figures 4B,C, respectively).
Despite the lack of statistically significant improvement, by
various parameters there appears some positive trend by
group median scores of improved TB disease outcome after
MTBVAC-HK boosting relative to BCG alone: for total
pathology score (Figure 4A), body weight development, and
infection-associated anemia by hematological mean corpuscular
hemoglobin (MCH) and mean corpuscular volume (MCV)
development (Supplementary Figures S5D,F,G, respectively).
Most notably, MTBVAC-HK boosting significantly suppressed
the PPD-specific IFNg response up until 6 weeks after infection
(Figures 4E–H). Also, the Mtb-specific response against an
ESAT6-CFP10 fusion protein (covering antigens which are
absent from M. bovis-derived BCG vaccine) is significantly
suppressed up until 6 weeks post-infection by MTBVAC-HK
boosting (Figures 4I–K). While we have recently established the
correlation between lower anti-Mtb IFNg responses following
challenge and protective immunity against infection and disease
in a repeated limiting dose (RLD) infection model in rhesus
macaques (Dijkman et al., 2019), we consider that these
unprecedented, suppressed PPD and ESAT6-CFP10 specific
responses might reflect the protective effect of MTBVAC-HK
boosting in this NHP model under relatively high-dose challenge
condition. Most likely because of the relatively high challenge
dose of 50 CFU of Mtb, we anticipate that, from 6 weeks
post-infection onward, disease in these highly susceptible rhesus
macaques can no longer be controlled. As a consequence,
pathology scores and mycobacterial counts at endpoint may have
converged to a similar outcome leaving a trend of improvement
by MTBVAC-HK boosting only.
MTBVAC HK Vaccination Induces
Mucosal Immunoglobulins in Vaccinated
NHP
MTBVAC HK mucosal vaccination induced a strong cellular
response both systemically and locally. However, considering the
results obtained in mice we focused further analyses on systemic
and local antibodies. To this end, we used sera and BAL samples
from vaccinated monkeys obtained along the study time line
to characterize humoral immune responses. PPD-specific IgG,
IgM and IgA kinetics were monitored in serum samples from
MTBVAC HK group during vaccination phase (from week 0 to
week 20). Specific IgG showed a significant increase at week
20, which was particularly pronounced in 4 of the 6 animals,
indicating a correlation between PPD-specific IgG and MTBVAC
HK vaccination (Figure 5A). In the case of IgM, no significative
changes were observed at the timepoints analyzed, although a
slight transitory increase was observed in two animals at week 17,
one week after MTBVAC HK inoculation (Figure 5B). Finally, the
PPD-specific IgA profile showed a decrease that correlated with
the administration of MTBVAC HK (Figure 5C).
We obtained BAL samples of three monkeys from the
MTBVAC HK group at two different timepoints: at week 13
(before MTBVAC HK booster immunization), and at week
20 (4 weeks after MTBVAC HK administration). Our results
clearly indicate that mucosal vaccination with MTBVAC HK
induced a substantial increment of PPD-specific IgA, IgG, and
IgM in the three animals studied, similar to the observations
in mice. In addition, we also observed an increase in J chain
presence, suggesting the presence of multimeric secretory IgA
and IgM (Figures 5D–G).
Our data demonstrate the induction of PPD-specific
immunoglobulins by MTBVAC HK. However, PPD comprises
the secreted fraction of M. tuberculosis proteome. Thus, we next
aimed to elucidate whether MTBVAC HK-induced mucosal Ig
could bind to M. tuberculosis bacilli. To this end, we incubated
H37Rv bacteria with BAL fluid samples, followed by biotin-
conjugated secondary antibodies specific for human IgM, IgG
and IgA. A final incubation step with PE-bound streptavidin
allowed visualization of Ig binding by flow cytometry. Our data
show a positive shift of the fluorescence signal for either of
the three immunoglobulin families, IgA, IgM, and IgG, when
bacteria had been incubated with BAL fluid from MTBVAC
HK-vaccinated animals, indicating the presence of IgA, IgM, and
IgG, able to bind to Mtb directly. This binding was substantially
higher in the case of IgM, which would correlate with the
pentameric conformation of this immunoglobulin. While for
the BCG only-vaccinated animals, the binding was similar to
that measured in BAL samples from unvaccinated animals,
the highest signals were obtained after MTBVAC HK boosting
specifically (Figure 5H).
H37Rv Opsonization Following
Incubation With MTBVAC HK-Derived
BAL
Phagocytosis mediated by antibody-dependant opsonization
represents a major bactericidal mechanism triggered by
immunoglobulins. To evaluate opsonization in our study, we
added H37Rv to human monocyte cells THP1, after it had
been incubated with the different BAL samples. We used GFP-
expressing bacteria in order to monitor internalization by flow
cytometry. Our data demonstrate about a two-fold increase of
infected cells when H37Rv had been previously incubated with
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FIGURE 4 | TB disease measures and IFNg responses after infectious challenge. (A–C) Total arbitrary score of pathological involvement at endpoint and for lung and
extra-thoracic disseminated disease, respectively. (D) Post-mortem enumeration of bacterial burden in the lung. (E–H) PPD-specific and (I–K) ESAT6-CFP10 fusion
protein (E6C10) specific IFNg responses by specific ELISPOT analysis of PBMC, at indicated timepoints relative to primary vaccination or infectious challenge.
Individual data points are consistently colored according to the Supplementary Table 1; fat horizontal lines indicate group medians.
BAL fluid from MTBVAC HK-vaccinated monkeys compared to
control groups (Figure 6A). Opsonization has been associated
with an increase in the capacity of macrophages to restrict
bacteria into acidic compartments. To assess this, we analyzed
intracellular colocalization of H37Rv with lysotracker, a probe
that becomes fluorescent under acidic conditions. In the three
monkeys analyzed, our results showed an increased bacterial
colocalization following pre incubation of H37Rv with BAL from
week 20 compared to those from week 13 (Figure 6B).
Our results showed great ability of BAL IgM and IgG to
bind Mtb surface. Complement activation in respiratory airways
has been previously reported, and therefore, since IgM and
IgG is a very efficient complement activators, we evaluated
the role of C3b, one of the major opsonins released during
complement activation, for MTBVAC HK vaccination-induced
opsonization. We incubated H37Rv with the different BAL
samples and then we added a C3b-specific antibody to detect
binding of this protein to Mtb surface by flow cytometry. In
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FIGURE 5 | Intrabronchial MTBVAC HK induces mucosal immunoglobulins in respiratory airways from non-human primates. (A–C) PPD-specific IgG, IgM, and IgA
were measured in sera samples from the different individuals throughout the vaccination phase (until week 20). (D–G) PPD- specific IgA, IgM, IgG, as well as J chain
were analyzed in BAL samples harvested at week 13 (before MTBVAC HK) and week 20 (after MTBAVC HK) from three individuals from the MTBVAC HK group.
Data in the graphs show values for each individual (H) Direct binding of IgA, IgM, and IgG to Mtb surface. H37Rv bacteria were incubated with BAL samples and
immunoglobulin binding measured by flow cytometry using specific secondary antibodies. Representative overlay histograms are shown. Black line: unvaccinated;
Red line: BCG vaccinated; Blue line: BCG/MTBVAC HK vaccinated. Data in the graphs show the mean fluorescence intensity (MFI) obtained with each BAL
compared to the measured when bacteria are incubated with PBS. (A–G) Data show individual from one experiment. (F) Data are shown as mean ± SEM and are
representative of two independent experiments. (A–C, H) *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by one-way ANOVA and Bonferroni post-test. (A–C)
Comparisons of the different timepoints with week 20 are shown. (D–G) *p < 0.05; **p < 0.01 by paired t-student test.
line with what was observed for the different immunoglobulin
subtypes previously, we detected a higher fluorescence peak of
C3b binding with the BAL from week 20 compared to week
13 (Figure 6C). Interestingly, preincubation of week 20 BAL
from two different individuals with anti-C3b partially prevented
Mtb phagocytosis, suggesting a functional role of this opsonin
in enhanced uptake (Figure 6D). These results do not rule
out that other opsonins released during complement activation
play a role in the enhanced uptake of Mtb after MTBVAC HK
booster vaccination.
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FIGURE 6 | Mucosal immunoglobulins induced by MTBVAC HK opsonize Mtb in vitro. GFP-expressing H37Rv coated with BAL samples were added to THP-1
human monocytes. (A) Percentage of infected cells was determined by flow cytometry 4 h post-infection. Representative dot-plots from one individual are shown in
the left panel. Data in the graph is represented as the fold-change of the percentage obtained with the BAL from BCG-only or BCG/MTBVAC HK compared with the
BAL from unvaccinated NHP. (B) Representative images of infected cells stained with lysotracker and Hoechst reagents. Data in the graph show colocalization
values for each individual from MTBVAC HK group comparing colocalization obtained with BAL from week 13 and 20. (C) C3b binding to H37Rv surface was
analyzed by flow cytometry using an antibody against C3b. A representative overlay histogram is shown. Black line: unvaccinated; Red line: BCG vaccinated; Blue
(Continued)
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FIGURE 6 | Continued
line: BCG/MTBVAC HK vaccinated. Data in the graph show the MFI fold-change obtained following incubation with BAL from week 13 and 20 compared to the
measured with the value when bacteria are incubated with PBS. (D) THP1 cells were infected with H37Rv previously incubated with BAL from week 20 in the
presence or absence of a neutralizing antibody antiC3b. (E) Fold-change comparison of infected- THP1 cells at 48 h versus 0 h for each experimental condition.
(A,E) Data in the graphs are mean ± SEM from a pool of three independent experiments. **p < 0.01; ****p < 0.0001 by one-way ANOVA and Bonferroni post-test.
(B) Data show mean values of at least six images for each experimental condition from one experiment. (C) Data show individual from one experiment. (B,C)
*p < 0.05 by paired t-student test. (D) Data in the graphs are mean ± SEM from a pool of two independent experiments. *p < 0.05 by two-way ANOVA and Sidak’s
multiple comparison test.
Finally, we analyzed the capacity of internalized bacteria to
spread from cell to cell. Our data indicate that percentage of
infected cells at 48 h of infection was about 2.5-fold higher when
compared to initial infection rate in cases where H37Rv had been
incubated with control BAL fluid (unvaccinated or BCG only),
whereas this ratio dropped to 1.5 with the BAL from MTBVAC
HK boosted animals (Figure 6E). This result suggests that the
ability of Mtb to spread to bystander cells was impaired when
bacteria were opsonized.
DISCUSSION
During the last years there is rising interest to elucidate the
role of immunoglobulins in tuberculosis infection. Different
studies using animal models have shown that pulmonary
delivery of monoclonal antibodies targeting certain Mtb surface
proteins leads to a reduction of bacterial load following
challenge (Achkar and Casadevall, 2013). In addition, results
from clinical vaccine trials suggest a correlation between
Mtb-specific IgG in sera and lower risk of TB disease
(Fletcher et al., 2016). An elegant study recently demonstrated
differences in glycosylation of immunoglobulin Fc fractions
between latent and active TB individuals, and the importance
of these signatures for antibody interaction with different
cellular subsets, suggesting a role of antibodies in natural
prevention of TB reactivation (Lu et al., 2016). Altogether,
these studies provide substantial support for the potential
contribution of antibodies to natural or vaccine-induced
protection against tuberculosis.
Nevertheless, there is a poor understanding about the
processes that drive to generation of protective antibodies
during tuberculosis infection, and vaccine strategies that
specifically exploit humoral responses are underrepresented
in the tuberculosis vaccine pipeline. In the present work,
we identify a novel vaccine approach that induces mucosal
protective antibodies in the lungs. We describe in mice how
a single intranasal immunization with a inactivated whole-cell
M. tuberculosis vaccine triggers lung protective immunity when
given as boost over previously BCG immunized animals. Data
from NHP studies also showed a tendency in the MTBVAC
HK-immunized group to improve protection in certain disease-
associated parameters, even though differences were not
statistically significant. Remarkably, results in NHP showing
MTBVAC HK-induced inhibition of PPD- and ESAT6/CFP10-
specific responses following Mtb challenge suggest a protective
role of MTBVAC HK in this animal model. However,
high dose challenge experimental conditions used in this
study may be obscuring the full protective potential of
MTBVAC HK boosting.
We show that mucosal administration of MTBVAC HK
induces strong cellular and humoral responses at both systemic
and local lung level, which correlates with an improved
protection compared to animals immunized only with BCG
by parenteral route. Our data evidence the importance of
the mucosal route of administration to trigger mucosal
immunoglobulins in the lungs. In this regard, we demonstrate
that intradermal BCG, the current vaccine regimen used in the
clinic, does not generate antibodies in the lung lumen, which is in
agreement with our previous observations (Aguilo et al., 2016).
Remarkably, MTBVAC HK fails to protect in the absence of
pIgR, a transporter protein that mediates release of secretory
Ig (sIg) to respiratory airways, suggesting a crucial role of
mucosal antibodies in the protective mechanism triggered by
this vaccination strategy. sIg comprise polymeric IgA (dimer)
or IgM (pentamer) molecules, covalently linked to J chain, and
the secretory component (SC), which corresponds to a pIgR
extracellular domain that is cleaved following translocation.
This complex conformation provides more stability to the
immunoglobulin, making it less susceptible to proteolytic
digestion and more mucophilic (Rojas and Apodaca, 2002).
Our results in mice suggest no contribution of IgGs to
MTBVAC HK-mediated protection, despite their presence in
BAL following immunization. Monomeric immunoglobulins
have lower capacity to neutralize pathogens in mucosal tissues
compared to polymeric conformations (Renegar et al., 1998). In
this regard, our results suggest a strong capacity of sIgA and sIgM
to impair M. tuberculosis infection.
Even though our data do not demonstrate greater
susceptibility of IgA-/- and pIgR-/- mice to Mtb infection
per se and therefore, no apparent role of sIg in natural TB
protection, the scenario changes when Mtb-specific sIg are
present in the respiratory airways prior to pathogen encounter.
Our in vitro functional assays using BAL fluid samples from
MTBVAC HK-vaccinated NHP indicate the capacity of vaccine-
induced sIg to bind directly to Mtb surface and to modulate
pathogen interaction with macrophages. Mtb incubation with
BAL from MTBVAC HK-immunized monkeys led to an increase
of the phagocytosis rate, a higher colocalization of intracellular
Mtb with acidic compartment tracer, and an impaired capacity
of bacteria to spread from cell to cell. Thus, our data suggest
antibody-mediated opsonization as a plausible protective
mechanism of MTBVAC HK vaccination.
Our results indicate similar MTBVAC HK-induced
protection in IgA-/- mice (where IgM is the only secretory
immunoglobulin available) compared to wild-type animals,
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suggesting a primordial role of sIgM in vaccine-induced
protective efficacy. However, our results are not sufficient to
determine that IgA have not contribution to vaccine-induced
protective response. A good approach to elucidate this point
could be the use of a mouse strain unable to produce secretory
IgM. This experiment should be performed in the future
to clarify this question. Unlike IgG and IgA, it is not well
defined up-to-date which receptor for IgM could drive IgM-
specific opsonization. However, IgM, including secretory IgM
(Michaelsen et al., 2017), is a strong complement activator, and
IgM-dependent opsonization by complement-derived opsonins
is well reported (Guidry et al., 1993). In addition, our results
also revealed an important binding of IgG to Mtb surface.
Since IgG is a strong complement activator, these antibodies
might also play a role in the bacterial opsonization events
described in this study. One of the major opsonins activated
during this process is C3b, released as a consequence of the
C3 proteolization by the enzyme C3-convertase. C3b presents
strong avidity of binding to bacterial surfaces directly, and it
mediates opsonization following recognition by CD35, a surface
receptor on macrophages, including the THP1 cells used in the
present study (Baqui et al., 1999). Our results suggest that, at least
partially, C3b generated following MTBVAC HK vaccination
has a role in Mtb opsonization. Although complement proteins
are mostly generated in the liver, lungs can be a local source of
complement proteins. In particular, alveolar epithelial cells, as
well as alveolar macrophages can secrete complement proteins
(Strunk et al., 1988; Huber-Lang et al., 2002).
Despite the lower immunogenicity and poorer protective
efficacy conferred by inactivated whole-cell tuberculosis vaccines
in comparison to their live counterparts, there is an interest
in the development of this type of vaccination strategies. As
inactivation is associated with an improved safety profile, such
vaccines are considered in particular for target populations to
which live vaccines might be harmful, such as immunosuppressed
individuals. Limited immunogenicity of inactivated vaccines is
usually overcome by other strategies, such as the formulation
of inactivated vaccines with adjuvants (Haile et al., 2004) or
repeated administration by multiple immunizations (Opie and
Freund, 1937; Von Reyn et al., 2017). In the case of intranasal
MTBVAC HK, our data indicate that it is not protective by itself,
but it needs of a previous BCG prime to trigger a response in
the lungs and confer protection. Even though we have not fully
studied the mechanisms behind this result, it could be interesting
to address the cross-talk between mucosal and systemic immune
compartments in the future. For now, we speculate that the
mucosal delivery of MTBVAC HK might be pulling the systemic
cellular response elicited by subcutaneous BCG toward the
lungs. Secondary targeting of the lung compartment with
inactivated bacilli, would be a relatively safe way of boosting the
cellular response and inducing specific antibodies locally against
whole-cell bacteria.
Our results do not clarify whether the present vaccination
approach is effective only when we use an M. tuberculosis-
based vaccine as MTBVAC, or whether it can be translated to
other whole-cell vaccines like inactivated BCG. In this regard,
a previous study reported no additional protection in the lungs
conferred by intranasal heat-killed BCG given as booster of
subcutaneous live BCG immunization (Haile et al., 2005). This
failure of boosting with inactivated BCG could highlight the
importance of the differential antigens expressed by MTBVAC
relative to BCG (Marinova et al., 2017), which are shared with
the M. tuberculosis pathogen. Indeed, contribution of differential
antigens to MTBVAC-conferred protection has been previously
reported in the case of live MTBVAC (Aguilo et al., 2017).
Nevertheless, comparison between inactivated MTBVAC and
BCG should be done head-to-head in order to confirm this
difference under the same experimental conditions.
The results from the present study indicate that a plausible
mechanism of protection of mucosal MTBVAC HK is mediated
by the generation of specific antibodies in the respiratory
airways, with capacity to opsonize live Mtb bacteria. We do
not discard that another inflammatory events mediated by the
vaccine as production of certain cytokines could also contribute
to protection. To our knowledge, this is the first tuberculosis




BCG Danish (Statens Serum Institute) and H37Rv (Institut
Pasteur Paris) strains were grown at 37◦C in Middlebrook
7H9 broth (Difco) supplemented with ADC 10% (Difco) and
0.05% (v/v) Tween-80 (Sigma), or on solid Middlebrook 7H11
(Difco) supplemented with ADC 10%. Bacterial suspensions for
vaccination or infection were prepared in PBS from glycerol
stocks previously quantified by plating serial dilutions. MTBVAC
HK vaccines were prepared by heating a log-phase MTBVAC
culture at 100◦C during 30 min. In the case of formalin
inactivation, MTBVAC culture was incubated with 0.5% (vol/vol)
formalin during 48 h. Culture viability was checked for each
vaccine lot. Bacterial density was determined by plating prior to
heat treatment, and was used to calculate MTBVAC HK dose for
in vivo studies.
Cell Lines
THP-1 cells were purchased to European Collection of Cell
Cultures (ECACC) (Lot Number 10/016). All the experiments
were done using cells with less than five passages from its
thawing. Mycoplasma absence in the cultured cells was confirmed
after finalizing the experiments using the MycoAlert PLUS
Mycoplasma Detection Kit (Lonza).
Animal Studies Approval
Mouse studies were conducted in agreement with European and
national directives for protection of experimental animals and
with approval from the Ethics Committee from University of
Zaragoza (approved protocols PI14/14, PI50/14, and PI33/15).
Ethical approval for NHP study was obtained from the
Dutch authorities prior to start, under dossier registration
number DEC726subB.
Frontiers in Microbiology | www.frontiersin.org 11 June 2020 | Volume 11 | Article 1339
fmicb-11-01339 June 17, 2020 Time: 15:53 # 12
Aguilo et al. Mucosal Immunoglobulins by Respiratory Vaccines
Mouse Study
All mice were kept under controlled conditions and observed for
any sign of disease.
Protective Efficacy
Female, 8–10 weeks-old C57BL/6 (Janvier Biolabs), pIgR-/- (a
kind gift from Gerard Eberl, Institut Pasteur Paris), IgA-/-
(MMRRC repository), or DBA/2J (Janvier Biolabs) mice were
vaccinated subcutaneously with 5 × 105 CFU BCG vaccine in
100 µl PBS. Four weeks post-vaccination, mice were intranasally
vaccinated with 107 MTBVAC HK bacteria in 40 µl of PBS. Four
weeks later, mice were challenged intranasally with 150 CFUs
H37Rv. Bacterial burden was assessed four weeks post-challenge
by plating homogenized lungs and spleen on solid medium.
A group of infected mice was sacrificed 1 day after challenge
in order to determine the initial bacterial load in lungs, which
resulted in approximately 20 CFU in all experiments. In the
experiments involving newborn animals, mice were vaccinated
subcutaneously with 2.5 × 105 BCG CFU in 50 µl PBS in
the first three days after birth. Unvaccinated controls were
inoculated with 50 µl of PBS. 107 MTBVAC HK was administered
intranasally eight weeks later (or 104 when indicated). Four weeks
later, mice were challenged with 150 CFUs of H37Rv for bacterial
burden determination, or 104 CFUs for survival evaluation. In
this latter case, disease-associated symptoms (including weight,
aspect and individual/social behavior) were monitored weekly,
and mice were humanely euthanized according to pre-established
endpoint criteria.
Immunogenicity
Four weeks after MTBVAC HK vaccination, mice were
euthanized and splenocytes and lung cells collected. 106 cells per
experimental timepoint were stimulated with Purified Protein
Derivative (PPD) (Statens Serum Institute, SSI) 5 µg/ml during
48 h for supernatants collection and cytokine detection by ELISA.
IL17A or IFNγ concentrations were determined with specific
ELISA commercial kits (MabTECH). For bronchoalveolar lavage
(BAL) collection, trachea was cannulated and BAL was performed
with 0.8 ml of ice-cold PBS. Supernatant was separated from
cells by centrifugation and frozen at −80◦C for further protein
detection analysis. For antibodies or J chain determination in
BAL, maxisorp ELISA plates (NUNC) were coated with 10 µg/ml
of PPD and incubated overnight at 4◦C. After a washing step
with PBS-Tween20 0.05% (v/v) buffer, plate was blocked with
Bovine Serum Albumin 1% (w/v) in washing buffer for 1 h at
37◦C. Then, plates were incubated with 100 µl of BAL during
90 min at 37◦C. Following washing, plates were incubated for 1 h
at 37◦C with the corresponding anti IgA, IgG, or IgM antibodies
conjugated with Horseradish Peroxidase (HRP) (Sigma Aldrich)
at a 1:10000 dilution. Finally, enzyme-substrate reaction was
developed using 3,3′,5,5′-Tetramethylbenzidine (TMB) (Sigma
Aldrich) as substrate, and reaction was stopped with H2SO4 0.1N.
NHP Study
Bacteria, Vaccination and Infectious Challenge
For primary vaccination of NHPs, clinical grade BCG
Danish 1331 (SSI, Copenhagen, Denmark) was reconstituted
according to manufacturer’s protocol and applied at a single,
standard human dose (of 5 × 105 CFU on average) by
intradermal injection.
Inactivated MTBVAC-HK booster vaccination in NHP was
established by endobronchial instillation of 1.95 × 108 CFU-
equivalent/10 mL/dose, targeting the lower left lung lobe. To
this end, one mL of MTBVAC-HK suspension (provided by
Biofabri) was added to 9 mL of sterile, isotonic saline solution
(Eurovet Animal Health B.V., Bladel, Netherlands) immediately
prior to administration.
M. tuberculosis (Mtb) strain Erdman K01 was prepared at
50 colony forming units (CFU) per 3 mL sterile, isotonic saline
per dose, for infectious challenge of NHPs by endobronchial
instillation targeting the lower left lung lobe. NHPs were
challenged in random order in a single session within 3 h from
the preparation of the inoculum, using a pool of 3 vials of Mtb
Erdman from−80◦C frozen stock.
Study Design, Handling and Sampling
Purpose-bred, adult, healthy, Indian-genotype rhesus macaques
(Macaca mulatta) were selected from BPRC’s breeding colonies
and stratified into treatment groups. Males and females were
represented at a 2:1 ratio per group (unless indicated otherwise;
see Supplementary Table 1). Animals, per gender, were socially
housed throughout the experiment in BPRC’s experimental
animal facilities at biosafety level three. Enrichment was provided
in the form of food and non-food items and welfare was
monitored by daily observation.
A schematic diagram of the study design is provided
in Figure 3A. After a brief period of acclimatization and
baseline measurements, animals were primed with BCG –
or left untreated as non-vaccinated controls – and BCG
vaccinees were either or not boosted with MTBVAC-HK
16 weeks later. Another 9 weeks later – that is 25 weeks
post-priming – all animals received an infectious challenge
with 50 CFU of Mtb Erdman into the lower left lung
lobe. Twelve weeks post-infection, animals were sedated
and euthanized by intravenous pentobarbital injection, and
subsequently submitted to full post-mortem evaluation and
assessment of pathological and bacteriological parameters of
infection and disease. Two animals of the non-vaccinated
control group reached a premature, humane endpoint due to
acute progressive disease development and were euthanized for
full post-mortem evaluation 6 and 11 weeks post-infection,
respectively (see Supplementary Table 1).
All animal handling was performed under ketamine sedation
(10 mg/kg, by intra-muscular injection). For pulmonary
endoscopic installation and additional relaxation, intramuscular
ketamine (5 mg/kg) was supplemented with medetomidine
(0.04 mg/kg) and an analgesic was sprayed into the larynx.
Peripheral blood was sampled by venepuncture at various time
points, as indicated in the Results section. For immunological
assays, peripheral blood mononuclear cells (PBMC) were
isolated from heparinized blood by standard Ficoll R©-based
gradient centrifugation using LymphoprepTM (Axis-Shield,
United Kingdom). Serum tubes were spun for 10 min at 1000 g
to harvest and store cell-free serum at −80◦C for further
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analysis at later time point. Serum samples were filter-sterilized
using 0.2 µm PVDF-membrane plates (Fisher Scientific) before
immune response analysis.
Standard hematological parameters were measured in fresh
EDTA blood on a Sysmex2000i system (Siemens). Standard
clinical chemistry values were determined in fresh serum samples
on a CobasTM Intregra 400+ platform (Roche Diagnostics).
Bronchoalveolar lavage (BAL) was collected by three times
consecutive instillation-and-harvesting of 20 mL prewarmed,
sterile 0.9% saline, targeting the lower left lung lobe with an
endoscope. BAL was collected 3 weeks before and 4 weeks after
MTBVAC-HK boosting from N = 3 pre-assigned animals of
the MTBVAC-HK booster group, and 3 weeks before boosting
also from N = 3 pre-assigned animals of the non-vaccinated
controls (see also Supplementary Table 1 and Figure 3A). After
passage over a 100 µm filter and centrifugation for 10 min at
400 g, supernatant was decanted and stored as BAL fluid at
−80◦C pending further analysis. BAL cell pellet was resuspended
in fetal calf serum-, glutamax- and penicillin/streptomycin-
supplemented RPMI culture medium for immediate use in
immune assays. BAL fluid samples were filter-sterilized using
0.2 µm PVDF-membrane plates (Fisher Scientific) before
immune response analysis.
NHP Post-mortem Evaluation
At study endpoint, gross pathology was arbitrarily scored
utilizing a predefined algorithm, adapted from Lin et al. (2009).
Lung lobes were slabbed into approximately 0.5 cm slices for
ample inspection and lesions were scored by size, frequency
and appearance. Extrathoracic organs (typically spleen, liver and
kidneys) were scored similarly, and lymph node involvement was
graded by size and appearance.
After gross pathological examination, lung lobes were minced
and spleen and lung-draining lymph nodes were passed over a
100 µm cell strainer (Greiner Bio One International), prior to
further homogenization using GentleMACS M tubes (Miltenyi
Biotec). Homogenates were frozen stored at -80◦C and later
thawed and serially diluted onto Middlebrook 7H10 plates for
enumeration of bacterial tissue burden.
NHP Immune Analyses
Immunogenicity of vaccination was measured by a lymphocyte
stimulation test using a specific NHP IFNg ELISPOT kit (U-
CyTech) for the readout of the frequency of IFNg producing
cells. In brief, 2 × 105 PBMC in supplemented RPMI culture
medium were incubated in triplicate in microtiter flat-bottom
plates for 24 h at 37◦C and 5% CO2, either or not in the presence
of specific antigen. Mtb-derived protein purified derivative (PPD,
Statens Serum Institute, Denmark) or Mtb-specific, recombinant
ESAT6-CFP10 fusion protein (E6C10, for short; a gift from
K. Franken, LUMC, Leiden) were used for in vitro recall
stimulation as indicated, both at a final concentration of
5 µg/mL. After overnight incubation cells were transferred to
specific anti-IFNg-coated filter plates (PVDF, Millipore) for an
additional overnight incubation. Spots were developed using
tetra-methylbenzidine substrate (MAbTech) and quantified on
an AELVIS automated reader.
Flow cytometry was used to measure intracellular IFNg
cytokine levels in CD4+ and CD8+ T lymphocytes from BAL.
In brief, BAL cells (at least 1 × 106 cells) were either or not
stimulated with PPD at a final concentration of 5 µg/mL in
supplemented RPMI for 3 h in the presence of costimulatory
antibodies against CD28 (PE-Cy7 conjugated) and CD49d.
Subsequently, Golgiplug (BD Biosciences) was added and cells
were incubated for another 15 h at 37◦C and 5% CO2. Cells were
then stained by standard procedures using Cytofix/Cytoperm and
PermWash buffer (all from BD Bioscience), using the following
antibody conjugates: anti-CD20-V450, anti-CD3-V500, anti-
CD4-PerCP-Cy5.5, anti-CD8a-APC-Cy7, and anti-IFNg-AF700.
T lymphocytes were gated as singlets, CD20-negative, CD3-
positive cells. Within this population CD4+ and CD8+ cells were
interogated for cytokine production (Supplementary Figure S6).
Cells were measured in a LSR-II flowcytometer (BD Biosciences);
data were analyzed using FlowJo software.
PPD-specific IgA, IgM and IgG in sera and BAL samples, as
well as J chain in BAL, were determined following a protocol
similar to the one described above for mice. For J chain
determination, plates were incubated with a primary monoclonal
antibody anti J chain (Santa Cruz Biotechnology, sc-271967)
at a 1:1000 dilution, followed by incubation with secondary
anti mouse IgG. Serum samples were diluted 1:500 in all cases,
whereas BAL fluid was used undiluted. Anti human IgA, IgG or
IgM antibodies were all conjugated with HRP (Sigma Aldrich)
and diluted 1:10000. Primary anti J chain antibody was the same
as described above for mice.
Functional Studies With BAL Samples
To evaluate direct Ig binding to Mtb, 107 GFP-expressing H37Rv
in 50 µl of PBS were added to 50 µl of BAL (or PBS as
control) and incubated for 1 h at room temperature. Then,
anti human IgA, IgG or IgM antibodies, all biotin-conjugated
(Mabtech), were added in 50 µl at a final dilution of 1:200
(30 min at room temperature). Finally, streptavidin conjugated
with APC (Miltenyi Biotech) was added in 50 µl at a final
dilution of 1 µg/ml (30 min at room temperature). Bacteria were
fixed adding 300 additional µl of paraformaldehyde (PFA) (final
concentration 4%) and acquired with a flow cytometry Gallios
(Beckman Coulter). Use of GFP-expressing H37Rv allowed
discerning bacteria from BAL-derived debris. To assess C3b
binding, we used an anti C3b as primary antibody (Millipore,
clone 3E7) diluted at 1:25. Biotin-conjugated anti mouse IgG
(Bethyl), diluted 1:200, and APC-conjugated streptavidin were
used to detect fluorescence by flow cytometry.
THP-1 cells (Sigma-Aldrich) were cultured at 37◦C and 5%
CO2 in DMEM medium (Invitrogen) supplemented with 10%
inactivated foetal bovine serum (Biological industries) and 2 mM
glutamine (Biological industries). 5 × 105 cells were seeded in
24-plate wells and incubated overnight with PMA 10 ng/ml.
GFP-expressing H37Rv were incubated with the different BAL
samples (or PBS as control) as described above. When indicated,
anti C3b at 300 µg/ml was added to BAL suspensions. Then,
bacterial suspensions were prepared in DMEM complete medium
and put in contact with cells for 4 h at a MOI or five bacteria
per cell. Cells were washed three times with PBS and detached
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with trypsin to evaluate internalization by flow cytometry. In
some of the experiments, fresh media was added and GFP-
positive cells analyzed 48 h later. To assess bacterial colocalization
with acid compartments, cells seeded over microscopy slides
were incubated with 1 µM lysotracker red (Invitrogen). Then,
they were fixed with PFA and nuclei stained with Hoechst
33342 10 µg/ml. Images were acquired with an Olympus FV10-
i confocal microscopy. Colocalization was quantified using
FV10-ASW 3.0 software (Olympus), and was calculated as the
proportion of pixels that were both green and red compared
to those that were green. Percentage of colocalization was
determined analysing at least six images randomly taken for each
experimental condition.
Statistical Analysis
Results from this study were not blinded for analysis. No
randomization specific methodology was applied to this study.
No statistical method was used to calculate sample size in animal
experiments. GraphPad Prism six software was used for statistical
analysis. Statistical tests used for each experiment are indicated
in the figure legends. All statistical tests were two-tailed. Outlier
values were determined applying the Grubb’s test to all data sets,
and were discarded from the final statistical analysis. Differences
were considered significant at p < 0.05.
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